---
layout: minimal-medicine
title: Milrinone
---

# Milrinone
### Generic Name
Milrinone

### Usage
Milrinone is primarily used for the short-term treatment of acute decompensated heart failure in adults.  This means it helps improve the heart's pumping ability when the heart is suddenly struggling to function effectively.  It's an inotrope, meaning it strengthens the heart's contractions, and a vasodilator, meaning it widens blood vessels, thus reducing the workload on the heart.  While not its primary indication, Milrinone is also sometimes used off-label in other situations such as a bridge to heart transplant, for postoperative inotropic support in heart transplant recipients, and in the treatment of low cardiac output or septic shock in children (though efficacy and safety in children haven't been fully established).  It is crucial to understand that off-label use should only be considered under a doctor's close supervision.

### Dosage
Milrinone is administered intravenously (IV).  Dosages vary significantly depending on the patient's condition and response to treatment.  A healthcare professional will carefully monitor the patient and adjust the dose accordingly.

**Adults:**

* **Acute decompensated heart failure:** Typically begins with a 50 mcg/kg bolus given slowly over 10 minutes, followed by a continuous infusion of 0.375-0.75 mcg/kg/min. The maintenance dose can be up to 1.13 mg/kg/day.
* **Off-label uses (bridge-to-transplant, post-transplant support):**  Dosage is highly individualized, typically starting at a lower infusion rate (e.g., 0.125 mcg/kg/min) and titrated upwards based on clinical response and hemodynamic parameters.

**Children:**

Dosage in children is not established, and off-label use (e.g., low cardiac output, septic shock) may involve a loading dose of 50 mcg/kg given over 10-60 minutes, followed by a continuous infusion of 0.25-0.75 mcg/kg/min.  However, the safety and effectiveness in children require careful monitoring by a specialist.

**Dosage Adjustments:**  Dose adjustments are necessary for patients with impaired renal function.  The dosage is typically reduced based on creatinine clearance (CrCl).  The specific adjustments depend on the CrCl level and should be determined by a physician.  No specific dosage adjustments are recommended for hepatic impairment.

### Side Effects
Common side effects can include:

* Ventricular arrhythmias (irregular heartbeat)
* Headache
* Hypotension (low blood pressure)
* Supraventricular arrhythmias (irregular heartbeat originating above the ventricles)
* Angina pectoris (chest pain)
* Chest pain

Less common but serious side effects include:

* Anaphylaxis (severe allergic reaction)
* Atrial fibrillation (irregular heartbeat)
* Bronchospasm (constriction of the airways)
* Hepatic insufficiency (liver failure)
* Hypokalemia (low potassium levels)
* Injection site reactions
* Myocardial infarction (heart attack)
* Skin rash
* Thrombocytopenia (low platelet count)
* Torsades de pointes (a type of dangerous irregular heartbeat)
* Tremor

If any adverse effects occur, it's crucial to seek immediate medical attention.

### How it Works
Milrinone inhibits phosphodiesterase-3 (PDE3), an enzyme that breaks down cyclic adenosine monophosphate (cAMP). By inhibiting PDE3, Milrinone increases the levels of cAMP within heart muscle cells and blood vessels.  Increased cAMP strengthens the heart's contractions (positive inotropic effect) and relaxes blood vessels (vasodilation).  This combined effect improves the heart's ability to pump blood and reduces the pressure against which it has to work.

### Precautions
* **Contraindications:** Milrinone is contraindicated in individuals with hypersensitivity to milrinone or inamrinone (a related drug).
* **Interactions:** Use with anagrelide should be avoided due to the increased risk of inotropic effects.  Other drug interactions are possible; discuss all medications with your doctor.
* **Warnings:**  Milrinone should be used with caution in patients with atrial fibrillation or flutter, hypertrophic subaortic stenosis, electrolyte imbalances (especially hypokalemia), hypotension, recent myocardial infarction, renal impairment, and those who are breastfeeding.  Careful monitoring of heart rate, blood pressure, and ECG is vital.
* **Pregnancy and Lactation:** Milrinone is classified as pregnancy category C, meaning its effects on a developing fetus are not fully known.  Use during pregnancy should only be considered if the potential benefit outweighs the risk.  Excretion in breast milk is unknown; caution is advised if breastfeeding.

### FAQs

* **Q: How long can I take Milrinone?** A: Milrinone is intended for short-term use.  The duration depends on your specific condition and response to treatment; your doctor will determine the appropriate length of therapy.
* **Q: Can I take Milrinone with other medications?** A:  Discuss all your current medications with your doctor before starting Milrinone to prevent potential interactions.
* **Q: What should I do if I miss a dose?** A: Never double a dose; contact your healthcare provider for guidance.
* **Q: How is Milrinone stored?** A: Follow the storage instructions provided by your pharmacist.  Protect from light and extreme temperatures.
* **Q: Can I drive while taking Milrinone?** A:  If you experience side effects like dizziness or blurred vision, avoid driving or operating machinery.
* **Q: Is Milrinone addictive?** A: Milrinone is not considered an addictive substance.


**Disclaimer:** This information is intended for educational purposes only and does not constitute medical advice. Always consult a healthcare professional for any health concerns or before making any decisions related to your health or treatment.  The information provided here may not encompass all possible side effects, precautions, or interactions.  Always refer to the official prescribing information for complete and up-to-date details.
